Dacomitinib

What is Dacomitinib?

Dacomitinib is a prescription medication used in the treatment of certain types of lung cancer. It belongs to a class of drugs known as epidermal growth factor receptor (EGFR) inhibitors, specifically a type of tyrosine kinase inhibitor (TKI). Marketed under the brand name Vizimpro, Dacomitinib is a targeted therapy designed to block specific pathways that promote cancer cell growth. Unlike traditional chemotherapy, it focuses on molecular targets found in cancer cells, often resulting in different side effect profiles.

This medication is primarily indicated for patients with specific genetic mutations in their cancer, making it a personalized treatment approach. Its development represents a significant advancement in the management of advanced forms of non-small cell lung cancer (NSCLC).

How Does it Work?

Dacomitinib functions by irreversibly binding to and inhibiting the activity of the epidermal growth factor receptor (EGFR). EGFR is a protein found on the surface of cells that plays a crucial role in cell growth, division, and survival. In many types of cancer, particularly certain forms of non-small cell lung cancer (NSCLC), EGFR can become overactive or mutated, leading to uncontrolled cell proliferation and tumor growth.

By irreversibly blocking EGFR, Dacomitinib prevents the signaling pathways that fuel cancer cell growth and survival. This action helps to slow down or stop the progression of the disease. It is particularly effective in cancers that have specific EGFR mutations, such as exon 19 deletions or exon 21 L858R substitutions, which make the cancer cells highly dependent on EGFR signaling for their survival.

Medical Uses

Dacomitinib is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations. These specific mutations are identified through genetic testing of the tumor tissue, which is crucial before initiating treatment with Dacomitinib. It is used in patients whose cancer has spread to other parts of the body (metastatic) and who have not previously received systemic therapy for their metastatic disease.

Its role as a first-line treatment means it is typically the initial therapy chosen for eligible patients, offering a targeted approach to managing this aggressive form of cancer.

Dosage

The recommended dosage of Dacomitinib is 45 mg taken orally once daily, with or without food. It is crucial to take the medication at approximately the same time each day. If a dose is missed, patients should not take an extra dose to make up for the missed one; instead, they should take the next scheduled dose at the usual time. Patients should swallow the tablets whole and not crush, chew, or split them.

Dose adjustments may be necessary based on the patient's tolerance and the severity of side effects. Your doctor may temporarily interrupt treatment or reduce the dose if you experience certain adverse reactions. It is vital to follow your healthcare provider's instructions carefully and not to alter your dose without consulting them.

Side Effects

Like all medications, Dacomitinib can cause side effects, though not everyone experiences them. Common side effects often include:

• Diarrhea: This is very common and can sometimes be severe. Management often involves anti-diarrheal medications and hydration.
• Skin reactions: Rash, acne-like eruptions, and dry skin are frequently reported.
• Stomatitis: Inflammation and sores in the mouth.
• Nail changes: Such as paronychia (inflammation around the nails) or brittle nails.
• Fatigue: Feeling unusually tired or lacking energy.
• Decreased appetite: Leading to weight loss in some cases.
• Conjuctivitis: Redness or irritation of the eyes.

More serious, though less common, side effects can occur and require immediate medical attention. These include:

• Interstitial Lung Disease (ILD): Symptoms may include new or worsening shortness of breath, cough, or fever.
• Severe Dermatologic Reactions: Including Stevens-Johnson syndrome or toxic epidermal necrolysis, though rare.
• Severe Diarrhea and Dehydration: Which can lead to kidney problems.

It is important to discuss any side effects with your doctor, who can provide guidance on managing them or adjust your treatment if necessary.

Drug Interactions

Dacomitinib can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Key interactions include:

• CYP3A Inhibitors and Inducers: Strong inhibitors of CYP3A (e.g., ketoconazole, clarithromycin) can increase Dacomitinib levels, while strong inducers (e.g., rifampin, phenytoin) can decrease them. Dose adjustments of Dacomitinib may be necessary.
• Gastric pH-Elevating Agents: Medications that reduce stomach acid, such as proton pump inhibitors (PPIs) (e.g., omeprazole) and H2-receptor antagonists (e.g., ranitidine), can decrease the absorption of Dacomitinib. It is generally recommended to avoid concomitant use. If an acid-reducing agent is necessary, an antacid can be considered, but it should be taken at least 2 hours before or 10 hours after Dacomitinib.
• P-glycoprotein (P-gp) Inhibitors: Dacomitinib is a substrate of P-gp, so concomitant use with P-gp inhibitors may increase Dacomitinib exposure.

Always inform your healthcare provider about all medications you are taking, including over-the-counter drugs, herbal supplements, and vitamins, to ensure safe and effective treatment with Dacomitinib.

FAQ

Q: Is Dacomitinib a form of chemotherapy?

A: No, Dacomitinib is not traditional chemotherapy. It is a targeted therapy, specifically an EGFR tyrosine kinase inhibitor (TKI), which works by targeting specific mutations and pathways in cancer cells, rather than broadly killing rapidly dividing cells like conventional chemotherapy.

Q: How should Dacomitinib be stored?

A: Store Dacomitinib tablets at room temperature, away from moisture and heat. Keep them in their original container and out of reach of children.

Q: What should I do if I miss a dose of Dacomitinib?

A: If you miss a dose, take it as soon as you remember, unless it is less than 12 hours before your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once to make up for a missed dose.

Q: Can Dacomitinib be used in pregnant women?

A: Dacomitinib can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment and for at least 17 days after the last dose. Men with female partners of reproductive potential should use effective contraception during treatment and for at least 17 days after the last dose.

Products containing Dacomitinib are available through trusted online pharmacies. You can browse Dacomitinib-based medications at ShipperVIP or Medicenter.

Summary

Dacomitinib (brand name Vizimpro) represents an important targeted therapy for patients with specific types of metastatic non-small cell lung cancer (NSCLC) that carry EGFR exon 19 deletion or exon 21 L858R substitution mutations. By irreversibly inhibiting the EGFR pathway, it helps to control cancer cell growth and proliferation. While effective, it is associated with a range of side effects, notably diarrhea and skin reactions, and requires careful management and monitoring. Patients should adhere strictly to their prescribed dosage and be aware of potential drug interactions to ensure optimal treatment outcomes and minimize risks.